Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting
Welcome to the COPCOV team in the Dudley Group
Today Dudley Group Hospital Trust opened recruitment to COPCOV joining Brighton and Sussex Hospitals, Oxford University Hospitals, University Hospitals of Coventry and Warwickshire, Imperial College Healthcare and Morecambe Bay as the study moves towards national role out.
Welcome to the COPCOV team in Morecambe Bay
Today Morecambe Bay Hospital Trust opened recruitment to COPCOV joining Brighton and Sussex Hospitals, Oxford University Hospitals, University Hospitals of Coventry and Warwickshire and Imperial College Healthcare as the study moves towards national role out.
Hydroxychloroquine doses in COVID-19 prevention trials should be safe, study finds.
These Scientists Are Still Studying The World’s Most Controversial Drug,
COPCOV study recruits 100 health care workers in the UK
COPCOV Global Study Team Newsletter
Welcome to the COPCOV team in Coventry
Today University Hospitals of Coventry and Warwickshire opened recruitment to COPCOV joining Brighton and Sussex Hospitals, Oxford University Hospitals and Imperial College Healthcare as the study moves towards national role out.
COPCOV study has continued importance
COPCOV investigators Prof Martin Llewelyn and Dr Will Schilling set out the continued importance of the Trial following the publication of negative trials assessing hydroxychloroquine for treatment of COVID-19: Pharmaceutical journal article.
Hydroxychloroquine being 'discarded prematurely', say scientists
COPCOV on Sky news
Coronavirus: Oxford study says hydroxychloroquine can not be 'ruled out' as preventative measure, article
COPCOV study recruitment has resumed
This weekend the UK Medicines Healthcare Regulatory Agency has approved further enrolment into the COPCOV trial. We are beginning recruitment again this week and will be working hard to open sites across the UK during July.
Pause in recruitment
We received notice from the UK's MHRA (Medicines and Healthcare Products Regulatory Agency) to pause for now new enrolment into our COPCOV study. We responded promptly to the MHRA, addressing their concerns in detail and await their decision. For now, COPCOV study enrolment is paused around the globe. The safety of our participants is our first priority, as is preventing illness in front-line healthcare workers.
First UK COPCOV site news
First UK site confirms Capacity and Capability at Brighton and Sussex University Hospitals NHS Trust
UK approval given for COPCOV study
Approval given by the Health Research Authority and Care Research Wales for COPCOV to go ahead in England and Wales
First COPCOV participant enrolled
First participants enrolled into the COPCOV trial in Thailand. Further details here
COPCOV in the news
Article in Science Magazine highlights COPCOV to evaluate role of pre-exposure prophylaxis in protecting healthcare workers from COVID-19